Added to YB: 2026-08-18
Pitch date: 2026-08-15
ETON [neutral]
Eton Pharmaceuticals, Inc.
+4.36%
current return
Author Info
Multibagger Ideas researches and shares thesis-driven ideas on potential multibaggers. Sign up for the newsletter.
Company Info
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Market Cap
$1.7B
Pitch Price
$59.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
66.56
P/E
137.52
EV/Sales
15.96
Sector
Pharmaceuticals
Category
growth
Up 247% - Eton Pharmaceuticals Q2 Earnings
ETON (earnings): Q2'26 rev $37.6M (+99% YoY), adj EBITDA $16.2M (43% margin), GAAP NI $11.6M ($0.35/sh) vs loss. FY26 guide raised to >$145M rev, ≥35% EBITDA margin. Net debt-free, no dilution. 11 rare disease products. Up 247% since Nov'25 writeup. Watch: HEMANGEOL patent exp Oct'28, ET-700 pilot weeks away, Q3 HEMANGEOL read, rising receivables (66% of rev). 2030 target $500M rev.
Read full article (10 min)